Home
This site is intended for healthcare professionals

Key Clinical Summary: Individualized Management and Treatment Optimization in Adult LOPD

This is a summary of Enduring Module presented by expert Professor Tahseen Mozaffar, MD which you can find here:
Module 3: Individualized Management and Treatment Optimization in Adult LOPD

Before participating, please read our CME and disclosure information which can be found in all of the links above.

This program is supported by an independent education grant from Amicus. This online education program has been designed for healthcare professionals in the US.

Treatment Optimization Framework and EPC Consensus Criteria

  • Consensus Framework: Reassessing treatment response in Late-Onset Pompe Disease (LOPD) relies on structured, repeatable criteria—such as the European Pompe Consortium (EPC) 2024 Start, Switch, and Stop (Triple-S) recommendations—to move management decisions from clinical opinion to standardized assessment.
  • ERT Initiation Criteria: Treatment is indicated upon confirmed diagnosis of Pompe disease combined with symptomatic skeletal muscle weakness and/or respiratory muscle involvement. Supportive muscle MRI can assist decision-making in select cases while weighing residual function, comorbidities, and patient commitment.
  • ERT Switching Criteria: A treatment switch may be considered when skeletal or respiratory function has failed to stabilize or improve after 12 or more months of therapy, or in cases of severe, unmanageable infusion-associated reactions. Because evidence that switching improves outcomes remains evolving, decisions must be made case-by-case through shared decision-making and monitored for at least 12 months post-switch.
  • ERT Discontinuation Criteria: Stopping therapy should be considered for severe unmanageable infusion-associated reactions despite switch consideration, high neutralizing antibody titers with diminished clinical response, explicit patient preference, complete lack of stabilization/improvement in the first 2 years post-start or switch, or end-of-life care.
  • Peak-Anchored Therapeutic Corridor: An emerging 2026 position statement proposes a peak-anchored, multi-domain therapeutic corridor for tracking loss of benefit; this serves as a proposed framework awaiting prospective validation.

Appraisal of Approved Disease-Modifying Regimens and Pipeline Approaches

  • Alglucosidase Alfa: First-generation recombinant human GAA (rhGAA) administered intravenously every two weeks. Pivotal LOTS trial data established its natural history-altering baseline (+28.1 meters 6-Minute Walk Distance [6MWD], +3.4 percentage points Forced Vital Capacity [FVC] over 78 weeks).
  • Avalglucosidase Alfa: Next-generation rhGAA engineered with enhanced cation-independent mannose-6-phosphate (M6P) targeting for increased lysosomal enzyme uptake, administered intravenously every two weeks. Pivotal COMET trial data in treatment-naive adults demonstrated FVC non-inferiority (+2.4 percentage points vs alglucosidase alfa) and secondary improvements in 6MWD (+30 meters).
  • Cipaglucosidase Alfa plus Miglustat: Combination therapy pairing a two-weekly intravenous rhGAA with an oral active-site stabilizer (miglustat) to improve enzyme stability in circulation. Pivotal PROPEL trial data demonstrated primary non-inferiority, with US indication specifically approved for adults not improving on their current enzyme replacement therapy.
  • Class Safety Profile: Infusion-associated reactions (IARs) and hypersensitivity are class effects across all available ERTs requiring ongoing monitoring. No adequately powered head-to-head clinical trials exist to rank overall efficacy among all three regimens.
  • Investigational Pipeline Approaches: Early-phase investigational strategies include adeno-associated virus (AAV) GAA gene transfer (aiming for durable endogenous enzyme production) and oral substrate reduction therapy via glycogen synthase inhibition (evaluated as an adjunctive add-on to ERT).

Individualizing Management: Four Core Clinical Inputs

When considering management adjustments or supportive care interventions, four key inputs must be evaluated and weighted together:

  1. Disease Stage and Trajectory: Assess remaining functional reserve, speed of overall decline, and domain-specific progression. Respiratory trajectory carries particular clinical weight due to the risk of respiratory failure.
  2. Comorbidities and Context: Factor in cardiopulmonary disease, metabolic status, age, frailty, musculoskeletal limitations, and existing support systems that alter risk profiles and therapeutic expectations.
  3. Treatment Burden: Evaluate biweekly lifetime intravenous infusion requirements, oral co-administration requirements, monitoring visit demands, and cumulative patient infusion fatigue.
  4. Patient Priorities and Goals: Align choices with what the patient is optimizing for (e.g., maintaining full-time employment, preserving independent mobility, avoiding daytime mechanical ventilation).

Multidisciplinary Team (MDT) Coordination and Parallel Care Streams

  • Parallel Care Streams Principle: Supportive care interventions and disease-modifying ERT reassessments must run concurrently rather than sequentially. Initiating non-invasive ventilation (NIV) or physical therapy does not delay or preclude ERT modification, and changing ERT does not replace supportive measures.
  • Neuromuscular / Metabolic Specialist: Leads ERT reassessment against formal consensus criteria, tracks longitudinal muscle strength/function, and coordinates overall disease management.
  • Pulmonology / Sleep Medicine: Evaluates respiratory muscle deterioration, conducts sleep studies, and initiates/titrates nocturnal NIV for confirmed hypoventilation.
  • Rehabilitation / Physical Therapy: Designs tailored exercise and mobility programs, conducts fall risk assessments, and protects functional reserve.
  • Cardiology: Provides baseline and periodic structural and electrophysiological cardiac screening as indicated.
  • Genetics and Counseling: Confirms variant interpretation, conducts family cascade testing, and evaluates clinical trial eligibility.
  • Nursing and Care Coordination: Manages infusion administration, captures serial patient-reported outcome (PRO) measures, and maintains multi-specialty care continuity.

Shared Decision-Making and Clinical Documentation Standards

  • Clarifying Expectations: Discuss the realistic scope of management options with patients, emphasizing that switching ERT primarily aims to stabilize a declining trajectory rather than restore historical peak function.
  • Defining Named Response Criteria: Translate individual patient priorities (such as maintaining employment or avoiding daytime ventilation) into explicit, measurable response criteria recorded in the medical chart.
  • Collaborative Choice: Put framework criteria on the table, review balanced evidence alongside treatment burdens, and apply patient values to finalize decisions when evidence does not strictly differentiate options.
  • Longitudinal Documentation Standards: Every management letter should explicitly record:
    • Established baseline and peak-on-treatment reference values.
    • Multi-domain trajectory statement across motor, respiratory, structural, biochemical, and PRO metrics.
    • Status against EPC reassessment criteria.
    • Specific multidisciplinary care outcomes (e.g., NIV initiation, physical therapy referral).
    • Defined re-evaluation dates (e.g., 6 and 12 months) with a pre-agreed contingency plan if the selected management strategy fails to stabilize disease trajectory.

Content is accurate as of the date of release